At a crossroads for early medical treatment of persistent patent ductus arteriosus in preterm infants.
J Perinatol
; 44(10): 1534-1537, 2024 Oct.
Article
de En
| MEDLINE
| ID: mdl-38918573
ABSTRACT
Administration of early medical therapy for the patent ductus arteriosus has ebbed and flowed through the years, with a multitude of studies failing to demonstrate a reduction in morbidity or mortality from ductal closure in the preterm population. Concerningly, an increasing number of studies have demonstrated an increase in morbidity, such as bronchopulmonary dysplasia and mortality with the use of early medical therapy to close the ductus. Considering information regarding potential risk without clear benefit in an overall cohort of preterm patients with a patent ductus, use of early medical therapy is increasingly challenging to justify and necessitates studies that will aid in identifying a patient population that would benefit from ductal closure and timing of therapy.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Prématuré
/
Persistance du canal artériel
Limites:
Humans
/
Newborn
Langue:
En
Journal:
J Perinatol
Sujet du journal:
PERINATOLOGIA
Année:
2024
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique
Pays de publication:
États-Unis d'Amérique